W
WAVEMAN · COMPANY
MGRX · Mangoceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

MGRX

MANGOCEUTICALS, INC.
HEALTHCARE SERVICES · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · CIK 0001938046
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
7
13F, latest reported quarter
REVENUE GROWTH
-26.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
7 funds added or opened last quarter
below 96% of Healthcare Services
REVENUE
-26.0% year over year
below 91% of Healthcare Services
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
8.7% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
more than 85% of Healthcare Services
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -81.7%
-81.7%12M
-93%-54%-16%+22%2025-092025-102025-122026-032026-052026-072026-09 2025-11-19 · Hamilton Alex P. sold $152.5K2025-12-05 · JOHNSTON EUGENE M sold $11.3K2025-12-09 · JOHNSTON EUGENE M sold $6.0K2025-12-15 · JOHNSTON EUGENE M sold $3.9K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 7 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for MANGOCEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
JOHNSTON EUGENE M
CFO
SELL
2025-12-15
3,333.0
$3.9K
JOHNSTON EUGENE M
CFO
SELL
2025-12-09
5,000.0
$6.0K
JOHNSTON EUGENE M
CFO
SELL
2025-12-05
10,000.0
$11.3K
Hamilton Alex P.
Director
SELL
2025-11-19
125,000.0
$152.5K
Hamilton Alex P.
Director
SELL
2024-06-26
108,426.0
$34.7K
7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
CITADEL ADVISORS LLC
338,964.0 sh
$128.8K
XTX Topco Ltd
186,256.0 sh
$70.8K
GEODE CAPITAL MANAGEMENT, LLC
156,243.0 sh
$59.4K
Ikarian Capital, LLC
138,146.0 sh
$52.5K
VANGUARD CAPITAL MANAGEMENT LLC
123,041.0 sh
$46.8K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$42.7K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$44.3K POSITION · AS OF 2026-03-31
0.0%
Fidelity Series Total Market Index Fund
$7.7K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$6.7K POSITION · AS OF 2026-02-28
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$107.2K POSITION · AS OF 2026-03-31
0.0%
Fidelity Nasdaq Composite Index Fund
$242 POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$456.0K$615.9K$731.5K$8.9K
GROSS PROFIT$250.4K$380.0K$431.5K$4.8K
OPERATING INCOME$-18.0M$-8.0M$-9.2M$-2.0M
NET INCOME$-20.6M$-8.7M$-9.2M$-2.0M
EPS (DILUTED)-2.17-4.80-8.58-0.19
OPERATING CASH FLOW$-5.9M$-4.9M$-7.0M$-1.3M
CASH$1.5M$58.7K$739.0K$682.9K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →